India GLP-1 Weight-Loss Drugs Market to Reach USD 1.6 Billion by 2031, Growing at a 29% CAGR: How Semaglutide Generics, Price Cuts and Obesity Burden Are Opening a Mass Market

India GLP-1 Weight-Loss Drugs Market Overview

India has become one of the most closely watched GLP-1 markets after semaglutide went off patent. Neargoal Consulting estimates the market at about USD 0.2 billion in 2025, rising to USD 0.45 billion in 2026E and USD 1.6 billion by 2031, a 29% CAGR over 2026E-2031F, from a small base. The semaglutide patent expired in India on 20 March 2026, and more than 40 manufacturers are preparing launches.

India GLP-1 Weight-Loss Drugs Market at a Glance

Market Outlook

Our study estimates the market will grow at a 29% forecast CAGR (2026E-2031F) from USD 0.45 billion in 2026E, from a small base. The base case assumes that generic semaglutide expands patient numbers sharply but lowers average prices by 50-60%, that tirzepatide holds premium positioning, and that value growth moderates after 2028F as the price effect settles.

Figure 1: India GLP-1 Weight-Loss Drugs Market Size, 2021-2031F (USD Billion)

Source: Neargoal Consulting Analysis

Figure 2: India Semaglutide Monthly Price: Branded Versus Generic Entry

Source: Neargoal Consulting Analysis

Market Dynamics

Growth Drivers

• Semaglutide Patent Expiry. Indian companies can make and sell semaglutide without an innovator license from 20 March 2026.
• Price Competition. Novo Nordisk cut branded prices by up to 37% in November 2025, and generics are expected 50-60% below innovator prices, with one vial starting at USD 14.80 (INR 1,290) a month.
• Large Disease Burden. ICMR-INDIAB estimates 254 million adults with generalized obesity and 351 million with abdominal obesity, and diabetes affects 89.8 million adults.

Restraints

• Affordability. Even at generic prices, treatment is a recurring monthly expense that many households cannot sustain.
• Prescriber and Patient Awareness. Long-term use requires counseling, monitoring and lifestyle support.
• Supply and Quality. Injectables need cold chain handling, and many new brands raise quality control questions.

Opportunities

• Generic Semaglutide. More than 40 manufacturers preparing launches and 50 or more brands expected through 2026.
• Obesity and Diabetes Co-Management. Clinics and programs combining medication and lifestyle support.
• Pen and Delivery Device Innovation. Reusable pens and multi-dose vials lower cost.
• Export of Generics. Indian producers are tying up with partners for Asian and African markets.

Policy and Regulatory Landscape

Drug approvals and manufacturing standards are overseen by the Central Drugs Standard Control Organisation, which approved several semaglutide products ahead of patent expiry. Patent law and price controls affect innovator and generic pricing, and marketing rules govern promotion to prescribers. Cold chain and quality rules affect distribution. The full report assesses how approvals, pricing rules and patents affect launch timing and competition.

Segment Insights

The full report quantifies every segment; the highlights below cover Molecule, Brand Type, and Indication.

By Molecule

Tirzepatide and semaglutide dominate, with generics reshaping the semaglutide segment.

By Brand Type

Innovator brands hold most 2025 value, led by tirzepatide, which became India's top-selling medicine by value in October 2025. Generics are expected to take share of volume quickly after patent expiry, with several companies launching in different dose forms. Our analysis expects generics to lower average prices while widening patient numbers.

By Indication

• Obesity. Weight management, the main growth driver.
• Type 2 Diabetes. Established use, with 89.8 million adults affected.
• Other Indications. Related cardiometabolic conditions as evidence builds.

Geographic Insights

Demand starts in large urban markets with higher incomes and specialist access.

• Western India. Large urban centers with high specialist density.
• Southern India. High diabetes burden and strong hospital networks.
• Northern India. Large urban populations, including the capital region.
• Eastern India. Emerging demand with limited specialist access.

Competitive Landscape

Key participants include Novo Nordisk, Eli Lilly, Sun Pharma, Dr Reddy's, Zydus Lifesciences, Natco Pharma, Mankind Pharma and Biocon. Competition rests on price, brand strength, distribution and prescriber relationships. Domestic generic makers compete on cost and device formats, while innovators compete on efficacy and brand.

Key Developments, 2025-2026

• June 2025. Wegovy launches in India.
• October 2025. Mounjaro becomes India's top-selling medicine by value.
• November 2025. Novo Nordisk cuts branded semaglutide prices by up to 37%.
• 20 March 2026. The semaglutide patent expires in India and generics begin to reach shelves.

What This Means for Decision-Makers

• Generic Makers: Differentiate on device, supply reliability and prescriber support.
• Innovators: Defend premium positioning through efficacy data and patient programs.
• Clinicians and Hospitals: Build structured weight management pathways.
• Investors: Track volume, average price and persistence, not launches alone.

About the Report

Table 1: India GLP-1 Weight-Loss Drugs Market: Report Coverage

The research report, India GLP-1 Weight-Loss Drugs Market Outlook 2021-2031F - Market Size, Share, Trends, Opportunities, and Competitive Analysis - Segmented by Molecule (Semaglutide, Tirzepatide, and Other GLP-1 Drugs); Brand Type (Innovator Brands and Generics); Indication (Obesity, Type 2 Diabetes, and Other Indications); and Region, covers sales of GLP-1 receptor agonist drugs for weight management and diabetes in India, with a 2025 base year, a 2026E estimate and a 2027F-2031F forecast. It excludes non-GLP-1 diabetes and weight-loss drugs and compounded or unapproved products. Market estimates and projections are based on Neargoal Consulting’s proprietary research methodology, exhaustive primary and secondary research.